Reata Pharmaceuticals Inc (NASDAQ:RETA) – Equities researchers at Leerink Swann reduced their Q3 2018 earnings per share estimates for Reata Pharmaceuticals in a note issued to investors on Tuesday, September 4th, according to Zacks Investment Research. Leerink Swann analyst J. Schwartz now expects that the company will earn ($0.65) per share for the quarter, down from their previous forecast of ($0.63). Leerink Swann has a “Outperform” rating and a $116.00 price objective on the stock. Leerink Swann also issued estimates for Reata Pharmaceuticals’ Q4 2018 earnings at ($0.68) EPS, FY2018 earnings at ($2.22) EPS, FY2019 earnings at ($3.17) EPS, FY2020 earnings at ($1.17) EPS, FY2021 earnings at $1.11 EPS and FY2022 earnings at $6.04 EPS.

A number of other equities research analysts have also recently weighed in on RETA. ValuEngine upgraded shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, June 6th. BidaskClub cut shares of Reata Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 23rd. Zacks Investment Research upgraded shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Friday, July 13th. Robert W. Baird lifted their price target on shares of Reata Pharmaceuticals from $47.00 to $92.00 and gave the company an “outperform” rating in a research report on Tuesday, July 24th. Finally, Citigroup lifted their price target on shares of Reata Pharmaceuticals from $76.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $80.00.

Shares of RETA traded up $1.80 during trading on Friday, reaching $92.06. 212,993 shares of the company traded hands, compared to its average volume of 250,427. Reata Pharmaceuticals has a twelve month low of $19.31 and a twelve month high of $92.48. The stock has a market cap of $2.59 billion, a PE ratio of -46.26 and a beta of 2.69. The company has a debt-to-equity ratio of -0.47, a current ratio of 3.09 and a quick ratio of 3.09.

Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings data on Wednesday, August 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.34). The company had revenue of $7.57 million for the quarter, compared to analysts’ expectations of $9.11 million.

Several hedge funds and other institutional investors have recently bought and sold shares of RETA. MetLife Investment Advisors LLC purchased a new position in shares of Reata Pharmaceuticals in the fourth quarter valued at approximately $127,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Reata Pharmaceuticals in the first quarter valued at approximately $152,000. Cubist Systematic Strategies LLC purchased a new position in shares of Reata Pharmaceuticals in the second quarter valued at approximately $154,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Reata Pharmaceuticals by 53.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock valued at $191,000 after purchasing an additional 1,897 shares during the period. Finally, Voya Investment Management LLC purchased a new position in shares of Reata Pharmaceuticals in the second quarter valued at approximately $213,000. 46.63% of the stock is owned by institutional investors and hedge funds.

In other news, insider Elaine Castellanos sold 7,336 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The shares were sold at an average price of $50.81, for a total value of $372,742.16. Following the completion of the transaction, the insider now owns 140 shares of the company’s stock, valued at $7,113.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Keith Wayne Ward sold 4,750 shares of the firm’s stock in a transaction that occurred on Thursday, July 5th. The shares were sold at an average price of $36.62, for a total transaction of $173,945.00. Following the completion of the transaction, the insider now directly owns 4,750 shares of the company’s stock, valued at approximately $173,945. The disclosure for this sale can be found here. Company insiders own 31.69% of the company’s stock.

About Reata Pharmaceuticals

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Read More: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.